| Assessment Status | Rapid Review Complete |
| HTA ID | 23022 |
| Drug | Belimumab |
| Brand | Benlysta® |
| Indication | Belimumab is indicated as add-on therapy in patients aged five years and older with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy. |
| Assessment Process | |
| Rapid review commissioned | 24/04/2023 |
| Rapid review completed | 29/05/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of belimumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
